Hong Kong approves celebrity weight-loss drug, but experts say it’s not just to look good
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned against using it for cosmetic purposes without a doctor’s prescription. US drug giant Eli Lilly announced last month that Mounjaro,
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies ...
Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high ...
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss drug in Hong Kong as ...
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback